TOF COMMERCEPATENTAND TRADEMARKOFFICE U.S. DEPAR ORMPTO-1390(Modified) TO THE UNITED STATES TRANSMITTAL LET U.S. APPLICATIONNO. (IF KNOWN, SEE 37 CFR DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371 PRIORITYDATECLAIMED INTERNATIONALFILINGDATE INTERNATIONALAPPLICATIONNO. 10 March 1999 10 March 2000 PCT/GB00/00919 TITLEOF INVENTION Dose Protector for Inhalation Device APPLICANT(SFOR DO/EO/US Michael Birsha DAVIES Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information: This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include itens (5), 3. (6), (9) and (24) indicated below. The US has been elected by the expiration of 19 months from the priority date (Article 31). A copy of the International Application as filed (35 U.S.C. 371 (c) (2)) X is attached hereto (required only if not communicated by the International Bureau). has been communicated by the International Bureau. b. 🗵 is not required, as the application was filed in the United States Receiving Office (RO/US). An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). a. 🗌 is attached hereto. has been previously submitted under 35 U.S.C. 154(d)(4). b. 🗀 Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3)) are attached hereto (required only if not communicated by the International Bureau). have been communicated by the International Bureau. have not been made; however, the time limit for making such amendments has NOT expired.  $\Box$ have not been made and will not be made.  $\times$ An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).  $\Box$ An English language translation of the annexes of the International Preliminary Examination Report under PCT 10. Article 36 (35 U.S.C. 371 (c)(5)) A copy of the International Preliminary Examination Report (PCT/IPEA/409).  $\mathbf{X}$ 11. A copy of the International Search Report (PCT/ISA/210). 12. Items 13 to 20 below concern document(s) or information included: An Information Disclosure Statement under 37 CFR 1.97 and 1.98.  $\times$ 13. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. A FIRST preliminary amendment. 15.

16. 

A SECOND or SUBSEQUENT preliminary amendment.

17. A substitute specification.

18. A change of power of attorney and/or address letter.

19. 

A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.

20.  $\square$  A second copy of the published international application under 35 U.S.C. 154(d)(4).

21. 

A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).

23. Other items or information:

Copy of PCT Request
Copy of PCT Cover Sheet

PCTUS1/REV03

518 Rec'd PCT/PTO 0 6 SEP 2001

.S. APPLICAT	BNVO OF	149 SE	CFR	INTERNATIONALAPP PCT/GB00		NO.		1	OCKETNUMBER
4. The	following	ees are subr	nitted:.				CA	LCULATIONS	PTO USE ONLY
ASIC NATIO	NAL FEE	( 37 CFR 1.	.492 (a) (1) - (	(5)):					
☐ Neither i	international	preliminary	examination	fee (37 CFR 1.482) nor		1			
and Inter	rnational Se	arch Report	not prepared	by the EPO of JPO		\$1000.00	1		
USPTO	but Internat	ional Search	Report prepa	CFR 1.482) not paid to ared by the EPO or JPO		\$860.00			
but inter	rnational sea	rch fee (37	CFR 1.445(a)	CFR 1.482) not paid to (2)) paid to USPTO	. <b></b>	\$710.00			
Internation	ional prelim	nary examin	nation fee (37 ovisions of PC	CFR 1.482) paid to USI T Article 33(1)-(4)	PTO	\$690.00			
□ Intornati	ional prelim	inary evami	nation fee (37	CFR. 1.482) paid to USI	PTO	\$100.00			
and all c	claims satisf	TER AF	PROPRI	ticle 33(1)-(4)  ATE BASIC FEE	AMOU	• • • •		\$860.00	<u></u>
ircharge of \$1	130 00 for f	umishing the	e oath or decla	aration later than	□ 20	□ 30		\$0.00	
onths from the	ne earliest cl	NUMBER		FR 1.492 (e)).  NUMBER EXTR.	A	RATE	<u> </u>		
otal claims	_	30	- 20 =	10	x	\$18.00	_ _	\$180.00	
dependent cla	aims	2	- 3 =	0	x	\$80.00		\$0.00	
ultiple Depen	ndent Claim	(check if a	applicable)					\$0.00	<u> </u>
				ABOVE CALCU			+	\$1,040.00	
Applicant claims small entity status. (See 37 CFR 1.27). The fees indicated above are reduced by 1/2.								\$0.00	
					SUBTO	TAL =		\$1,040.00	
rocessing fee	of \$130.00 he earliest c	for furnishir aimed prior	ng the English	translation later than CFR 1.492 (f)).	□ 20	□ 30 <sub>+</sub>		\$0.00	
				TOTAL NATI	ONAL	FEE =		\$1,040.00	
ee for recordi	ing the encl	osed assignn	nent (37 CFR	1.21(h)). The assignmer 8 3.28, 3.31) (check if a	nt must be		J	\$0.00	
ccompanied t	by an approp	Trace cover	SHOOT (ST OFF	TOTAL FEES		SED =	=	\$1,040.00	
		<del></del>		* :		-	Aı	mount to be: refunded	\$
								charged	\$
a. 🗆	A check in	the amount	of	to cover the a	bove fees i	s enclosed.			
b. 🗵	Please charge my Deposit Account No. 07-1392 in the amount of \$1,040.00 to cover the above fees.  A duplicate copy of this sheet is enclosed.								
c. 🗵	to Deposit	Account N	o. <u>07-13</u>	ized to charge any additi  2 A duplicate cop	y of this sh	eet is enclose	ed.		
d. 🔲	TAXABILING Information on this form may become public Credit card								
NOTE: Whe 1.137(a) or (f	ere an appr b)) must be	opriate time filed and g	e limit under ranted to res	37 CFR 1.494 or 1.495 tore the application to p	has not be pending sta	en met, a po itus.	etition	to revive (37 Cl	FR
SEND ALL C	CORRESPO	NDENCE T	ro:		1 -	fore		878	
David J. Le	•					SIGNATUR	E	<u> </u>	
	¥ 711				1 (	James P.	Riek		
GlaxoSmith		Property				Jamies F.			
GlaxoSmith Corporate I Five Moore	Intellectual Drive, PO	Box 13398				NAME			
GlaxoSmith Corporate I Five Moore Research T	Intellectual Drive, PO riangle Par	Box 13398 k, NC 2770	09			NAME			
GlaxoSmith Corporate I Five Moore	Intellectual Drive, PO riangle Par 919-483-22	Box 13398 k, NC 2770	09			39,009	TION	NUMBER	
GlaxoSmith Corporate I Five Moore Research T Telephone:	Intellectual Drive, PO riangle Par 919-483-22	Box 13398 k, NC 2770		<b>347</b>		39,009 REGISTRA			
GlaxoSmith Corporate I Five Moore Research T Telephone:	Intellectual Drive, PO riangle Par 919-483-22	Box 13398 k, NC 2770	23	347 DEMARK OFFICE		39,009 REGISTRA Septembe			
GlaxoSmith Corporate I Five Moore Research T Telephone:	Intellectual Drive, PO riangle Par 919-483-22	Box 13398 k, NC 2770	23	J	المعتشد	39,009 REGISTRA			

1918 Recd POTIPIO 0 6 SEP 2001

CERTIFICATE OF N	MAILIN SY "EXPRE	SS MAIL"	(37 CFR 1.16,	Docket No. PG3619USW		
Serial No. 71 of PCT/GB00/00919	Filing Date		Examiner	Group Art Unit		
nvention: Dose Protecto	or for Inhalation Device					
I hereby certify that this	s <u>Patent application under</u>	r 35 USC 371 v (Identify	vith corresponding pape type of correspondence)	ers		
is being deposited with	h the United States Postal		-	Addressee" service under		
	nvelope addressed to: The		•			
20231-0001 on	September 6 2001					
	(Date)	_				
		Elaine Martens (Typed or Printed Name of Person Mailing Correspondence)				
		(1ypeu				
			Charling Fire am Fire 4	Tens 14US		
		· · · · · · · · · · · · · · · · · · ·	("Express Mail" Mailing L			
		ν .				
			general and the second			
	Note: Each paper n	nust have its own	certificate of mailing.			
•						